Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer

Hormone Research

Volumn 62, Issue 5, 2004, Pages 252-258

  Teillac, Pierre ^a   Heyns, Christiaan F ^b   Kaisary, Amir V ^c   Bouchot, Olivier ^d   Blumberg, Joëlle ^e  

^a SAINT LOUIS HOSPITAL   (France)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d HÔTEL DIEU   (France)

^e IPSEN   (France)

Author keywords

Androgen deprivation; Chemical castration rate; LHRH analogue; PSA levels

Indexed keywords

FLUTAMIDE; GONADORELIN DERIVATIVE; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER LOCALIZATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PAIN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLOW RELEASE FORMULATION; TESTOSTERONE BLOOD LEVEL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE; THERAPEUTIC EQUIVALENCY; TRIPTORELIN;

EID: 9244245286     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081629     Document Type: Article

References (26)

1. Caroll PR, Lee KL, Fuks ZY, Kantoff PW: Cancer of the prostate, Section 4; in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology, ed 6. Philadelphia, Lippincott-Raven, 2001, vol 1, pp 1418-1479.
2. Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC: Prostate-specific antigen promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999;59:2136-2141.
3. Byar DP: Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32:1126-1130.
4. Parmar H, Phillips RH, Lightman SL, Edwards L, Allen L, Schally AV: Randomised controlled study of orchidectomy vs. long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 1985;ii:1201-1205.
5. Parmar H, Edwards L, Phillips RH, Allen L, Lightman SL: Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol 1987;59:248-254.
6. Harris GW: Neural control of the pituitary gland; in Batliss LE, Feldberg W, Hodgkin Al (eds): Monographs of the Physiological Society, No 3. London, Arnold, 1955.
7. Schally AV, Arimura A, Kastin AJ, Matsuo H, Baba Y, Redding TW, Nair RM, Debeljuk L, White WF: Gonadotropin-releasing hormone: One polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 1971;173:1036-1038.
8. Dutta AS, Furr BJA: Chemistry and Bioscience Departments, Imperial luteinizing hormone releasing hormone (LHRH) analogues. Annu Rep Med Chem 1985;21:203-214.
9. Schally AV, Coy DH, Arimura A: LH-RH agonists and antagonists. Int J Gynaecol Obstet 1980;18:318-324.
10. Kiesel L: Molecular mechanisms of gonadotrophin releasing hormone-stimulated gonadotrophin secretion. Hum Reprod 1993;8(suppl 2):23-28.
11. Stojilkovic SS, Reinhart J, Catt KJ: Gonadotropin-releasing hormone receptors: Structure and signal transduction pathways. Endocr Rev 1994;15:462-499.
12. Soloway MS, Chodak G, Vogelzang NJ, Block NL, Schellhammer PF, Smith JA Jr, Scott M, Kennealey G, Gau TC: Zoladex versus orchiectomy in treatment of advanced prostate cancer: A randomized trial. Zoladex Prostate Study Group. Urology 1991;37:46-51.
13. Waxman J, Man A, Hendry WF, Whitfield HN, Besser GM, Tiptaft RC, Paris AM, Oliver RT: Importance of early tumour exacerbation in patients treated with long-acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed) 1985;291:1387-1388.
14. Thompson IM, Zeidman EJ, Rodriguez FR: Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990;144:1479-1480.
15. Labrie F, Dupont A, Belanger A, Lachance R: Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 1987;138:804-806.
16. Thebault J: Bioequivalence study of two sustained release formulations of triptorelin after single intramuscular administration in sixteen normal healthy volunteers. Ipsen Internal Report.
17. Bouchot O: Pharmacodynamic and pharmacokinetic study of triptorelin pamoate sustained release form (3 months) in patients with prostatic adenocarcinoma. Ipsen Internal Report.
18. Machin D, Campbell MJ: Statistical Tables for the Design of Clinical Trials. Oxford, Blackwell Scientific, 1987, chapt 4, pp 35-53.
19. Geller NL, Pocock SJ: Interim analyses in randomized clinical trials: Ramifications and guidelines for practitioners. Biometrics 1987;43:213-223.
20. Buck EC (ed): Prostate Cancer: Questions and Answers. Merit Publisher International, 1994.
21. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
22. Huggins C, Stevens RE Jr, Hodges CV: Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-223.
23. Klugo RC, Farah RN, Cerny JC: Bilateral orchiectomy for carcinoma of prostate. Response of serum testosterone and clinical response to subsequent estrogen therapy. Urology 1981;17:49-50.
24. Botto H, Richard F, Mathieu F, Camey M. Decapeptyl in the treatment of metastatic prostatic cancer. Comparative study with pulpectomy. Prog Clin Biol Res 1987;243A:199-206.
25. Boccardo F, Decensi A, Guarneri D, Rubagotti A, Massa T, Martorana G, Giberti C, Cerruti GB, Tani F, Zanollo A: Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: An Italian prostatic cancer project (PONCAP) study. Prostate 1987;11:243-255.
26. De Sy WA, de Meyer JM, Casselman J, De Smet R, Renders G, Schelfhout W, De Wilde P: A comparative study of a long-acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report. Acta Urol Belg 1986;54:221-229.